Alzheimer's Disease Research Center News
A massive study of medical and genetic data shows that people with a particular version of a gene involved in immune response had a lower risk of Alzheimer’s and Parkinson’s disease.
Which comes first: Depression or dementia? A team of scientists led by Victor Henderson, MD found that the risk of dementia more than doubles for people previously diagnosed with depression.
A genetic risk factor found virtually exclusively among people of at least partial African ancestry substantially boosts the risk of incurring Alzheimer’s disease — but only sometimes.
Life in Motion
In this podcst, hosted by Sam Kleckly, Dr. Sharon Sha discusses the importance of brain health and things we can all do to help prevent or slow neurodegenerative diseases.
Join Chris Hemsworth and our very own Sharon Sha, MD, MS, in exploring the boundaries of human potential in #LimitlessWithChrisHemsworth, a Disney+ Original series from National Geographic, streaming November 16 on Disney+.
What can we all be doing in the here and now to keep our brains in shape? Stanford Medicine neuroscientist Tony Wyss-Coray, PhD, discusses his findings in the field of cognitive rejuvenation.
Q&A with Sharon Sha MD, MS: Dr. Sha weighs in on how the brain controls our movements, behavior, thoughts and memories -- and how that changes when things go awry.
Researchers, led by Michael Greicius, MD, MPH
have discovered that a rare mutation inherited with the APOE4 gene
variant protects against Alzheimer's, shedding new light on ways to
counteract high-risk genes for the disease.
Katrin Andreasson discusses how immune cells can cause harmful brain inflammation and contribute to the development of neurodegenerative diseases like Alzheimer’s disease.
A new initiative on brain resilience will study the causes of cognitive decline – what may be done to prevent, delay, or reverse the decline – and what goes right for those who keep their cognitive abilities intact. Based at the Wu Tsai Neurosciences Institute, this scientific endeavor is being launched by a $75 million gift from Nike founder Philip H. Knight, MBA ’62, and his wife, Penny. Tony Wyss-Coray, the D. H. Chen Distinguished Professor II of Neurology and Neurological Sciences at Stanford, has been appointed the inaugural director of the Phil and Penny Knight Initiative for Brain Resilience.
Scientists have been trying to unravel the mysteries of why memory diminishes with age for decades. Now they have discovered a possible remedy — cerebrospinal fluid from younger brains.
Q&A with Tony Wyss-Coray about the lab's interest in exploring the role of the brain's vasculature in Alzheimer's disease and the implications of new findings for the search for better therapies.
In a Stanford study, sedentary mice appear to benefit from another same-aged mouse’s exercise - if they receive injections of its blood.
Alzheimer’s Disease Research Center renamed for Asad Jamal, Iqbal Farrukh
VJ Periyakoil, MD, professor of primary care and population health and associate dean of research for geriatrics and palliative care, just received the American Board in Internal Medicine or ABIM Foundation’s John A Benson Jr, MD Professionalism Article Prize for her article “Common Types of Gender-Based Microaggressions in Medicine.”
Researchers from Stanford University and the Mayo Clinic recently published a Perspective on the investigational drug aducanumab, which is under review by the Food and Drug Administration for the treatment of Alzheimer’s disease: The authors state, “Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. One trial was trending positive while the other showed no benefits from aducanumab. Post hoc analyses led the sponsor to assert that there was a sufficient efficacy signal to justify a new drug application as a treatment for Alzheimer’s disease. The sponsor claimed that subsets of participants receiving sufficiently high doses of aducanumab demonstrated benefits in both trials. In contrast, we identified alternative accounts for the apparent drug benefits in post hoc subgroups that are unrelated to dose effects. Biomarker data were consistent with target engagement, but no evidence was presented to correlate biomarker changes to cognitive benefits. Our analysis supports the conduct of a third, phase III trial with high-dose aducanumab. Aducanumab’s efficacy as a treatment for the cognitive dysfunction in Alzheimer’s disease cannot be proven by clinical trials with divergent outcomes.”
The research team, led by Dolores Gallagher Thompson, PhD, and Nusha Askari, PhD, and Jacqueline Hartman at the Stanford Red Barn Leadership Program, found that supervised activities, such as observing herd behavior, grooming horses and leading horses with a lead and halter, helped participants recognize and use non-verbal forms of communication.
The February 22, 2016 issue of Time Magazine covers the efforts of Dr. Longo and his team to develop a novel approach for Alzheimer’s therapy.
As part of the team at the Stanford Center for Memory Disorders, Sha is dedicated to studying ways to fight memory disorders and cognitive decline. “I think it’s fascinating to help people understand why” the brain isn’t functioning in the right way, she shares.
In a recent interview, neurologist Frank Longo discussed Alzheimer’s disease, recent research breakthroughs and the new Stanford Neuroscience Health Center, which he co-leads.
A cure for aging? A scientist behind a breakthrough technique seems to have found a way to reverse cognitive ageing effects on mice. Next, is to find out if it will work on humans.
A series of experiments has produced incredible results by giving young blood to old mice. Now the findings are being tested on humans. Ian Sample meets the scientists whose research could transform our lives.
Our understanding of Alzheimer’s disease is better than ever before. So why are we still so far from a cure?
In this Q&A, Michael Greicius discusses the causes, onset, progression and treatment of Alzheimer's disease. Greicius is an associate professor of neurology and neurological sciences and medical director of the Stanford Center for Memory Disorders.
Might young blood be the fountain of youth? asks Tony Wyss-Coray from Stanford University. The Professor of Neurology says blood transports messages between different organs, and young blood may be able to boost health, recharge the old brain and halt cognitive decline.
A new Stanford ADRC will receive nearly $7.3 million in funding over a five-year period to conduct interdisciplinary research on Alzheimer’s disease and related disorders. Victor Henderson, professor of health research and policy and of neurology and neurological sciences, will direct the center; Tony Wyss-Coray, professor of neurology and neurological sciences, will serve as co-director; Frank Longo, the George E. and Lucy Becker Professor and professor and chair of neurology and neurological sciences and Jerome Yesavage, professor of psychiatry and behavioral sciences, will serve as associate directors; and Michael Greicius, associate professor of neurology, will lead the center's imaging core.
Imaging studies have delineated brain networks consisting of discrete brain regions acting in synchrony. This view of the brain’s functional architecture has now been confirmed by a study showing coordination at the genetic level as well.
Michael Greicius, MD, MPH, professor of neurology & neurological sciences at Stanford, researches Alzheimer’s and has a bone to pick with media hype about Alzheimer’s research conducted in mice. What the mice have shouldn’t be considered the same condition, he says, so he’s termed it “mouseheimer’s.”
A panel of experts discussed Alzheimer's disease and its effects on women Monday in San Mateo. The panel included Michael Greicius, associate professor of neurology and neurological sciences and medical director of the Stanford Center for Memory Disorders, who is quoted here.
The number of women with Alzheimer's far exceeds that of men with the condition. Researchers at Stanford University found that carrying a copy of a gene variant called ApoE4 puts women at a substantially higher risk for Alzheimer's disease than men.
Neurologists Roberta Diaz Brinton and Michael Greicius discuss why it’s important to study women with Alzheimer’s as a distinct population, and why females might be more likely to develop the disease.
Members of research teams created through the Stanford Neurosciences Institute's Big Ideas in Neuroscience initiative spoke Jan. 23 at the World Economic Forum in Davos, Switzerland.
By splicing animals together, scientists have shown that young blood rejuvenates old tissues. Now, they are testing whether it works for humans.
Brain cells called microglia chew up toxic substances and cell debris, calm inflammation and make nerve-cell-nurturing substances. New research shows that keeping them on the job may prevent neurodegeneration.
Longo and his colleagues have pioneered the development of small-molecule drugs that might be able to restore nerve cells frayed by conditions such as Alzheimer’s.
Something in the blood of young mice has the ability to restore mental capabilities in old mice, which could spell a new paradigm for recharging aging brains.
Carrying a copy of a gene variant called ApoE4 confers a substantially greater risk for Alzheimer's disease on women than it does on men, researchers have found.